Ras-Raf-MEK-ERK
Selected indexed studies
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. (Cells, 2020) [PMID:31941155]
- Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. (Genes Dis, 2023) [PMID:37013062]
- Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation. (J Exp Clin Cancer Res, 2025) [PMID:40883741]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. (2020) pubmed
- Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. (2023) pubmed
- Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation. (2025) pubmed
- RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. (2019) pubmed
- Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. (2022) pubmed
- Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy. (2023) pubmed
- The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. (2023) pubmed
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. (2011) pubmed
- Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. (2013) pubmed
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. (2012) pubmed